“We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main list when the company had matured. I’m pleased that we now have reached this milestone, and that we have access to a high-quality investor base as we work towards our ambitious targets of long-term growth and value creation. Through our diversified portfolio of tests, we provide a solid foundation for growth and value creation. To deliver on our ambition, we aim to bring one additional product to market per year and expand market access through achieving additional regulatory approvals and commercial partners.”
Hilja Ibert, CEO Gentian Diagnostics ASA
About Gentian Diagnostics
Gentian’s portfolio of diagnostic tests contributes to early disease detection and faster availability of clinically relevant information, which lead to better treatment decisions. In addition, they contribute to improve laboratory productivity and cost-efficiency by leveraging PETIA technology, which enable 3-10x higher throughput than traditional immunoassay platforms. The tests target several large and growing disease areas such as infections and inflammation, kidney failure and congestive heart failure. Gentian has four established products, one product in market development, and two products in development with launches scheduled for Q4 2021 and Q1 2022, respectively. Gentian also has three undisclosed biomarkers in exploration and ‘proof of concept’ phases.